A white paper released this month by the Association for Accessible Medicines (AAM) says that brand-name drugs are behind high prescription drug costs, and that those costs aren’t only hurting patients’ financial wellbeing, but also endangering their health.
A white paper released this month by the Association for Accessible Medicines (AAM) says that brand-name drugs are behind high prescription drug costs, and that those costs aren’t only hurting patients’ financial wellbeing, but also endangering their health.
As many as half of all patients with chronic diseases may not take their medications as prescribed, due in part to cost, according to the white paper, and “Non-adherence is considered responsible for approximately 125,000 deaths, at least [10%] of hospitalizations, and a substantial increase in morbidity and mortality annually.”
The need for lower-cost therapies is especially critical for those patients receiving high-priced biologics drugs, says AAM, pointing to the more than $100 billion in annual spending on biologics in the United States alone. The white paper reports that “Women, lower-income and elderly patients would particularly benefit from access to biosimilar medicines.”
While the generic drug business model has been largely successful in driving down costs of small-molecule drugs, says AAM, the consolidation of wholesaler and pharmacy partnerships into 3 large purchasing groups “…creates an imbalance compared to a highly fragmented generic drug market with more than 200 generic drug manufacturers…as multiple manufacturers continue to compete for the business of only [3] purchasers, many previously profitable markets are closed to many manufacturers.” Furthermore, market entry for biosimilars and generics can be forestalled by anti-competitive practices, patent litigation, lack of regulatory clarity, and incentives to prescriber high-cost medicines in Medicare.
In order to spur competition and ensure the availability of lower-cost biosimilars, says AAM, Congress should enact the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, which would allow a generic or biosimilar drug developer to bring a civil action against the license holder of a novel drug if the latter declines to make available enough samples for testing as part of generic or biosimilar drug development. Additionally, AAM calls on policy makers to scrutinize potential “gamesmanship” in the patent system and to ensure that biosimilars have a level playing field in the Medicare marketplace.
AAM also calls for the repeal or modification of the Medicaid Generics Penalty, continued regulatory attention to complex generics, a focus on state drug-pricing laws to address the biggest drivers of cost increases, and increased use of generics in Medicare as key ways to maintain a healthy generics market.
“Unless policymakers take steps to address these challenges, the risk of shortages among generic drugs is likely to increase further, threatening patient health,” added AAM’s president and CEO, Chip Davis, in a statement.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.